## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.27 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($146.61)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation**
- Source: Nasdaq | 20251205T190400 | Bullish | Relevance: 100%
- TD Cowen has reaffirmed its "Buy" recommendation for Neurocrine Biosciences (NBIX). Analysts project a 15.00% upside, with an average one-year price target of $177.35/share. Funds and institutions show slight increases in ownership, despite a minor decrease in total institutional shares over the last quarter.

**2. Neurocrine Biosciences fails mid-stage study of depression drug**
- Source: MSN | 20251204T042204 | Bearish | Relevance: 100%
- Neurocrine Biosciences' mid-stage study for its depression drug failed to meet its primary endpoint. This setback signals a potential halt in the development of this particular candidate for major depressive disorder.

**3. Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZAâ€™s Clinical Profile**
- Source: Sahm | 20251203T042204 | Somewhat-Bullish | Relevance: 100%
- Neurocrine Biosciences saw a 5.1% increase after a peer-reviewed study reinforced the clinical profile of its FDA-approved drug, INGREZZA, for tardive dyskinesia. The review consolidates over a decade of research, highlighting INGREZZA's distinct pharmacologic and dosing characteristics compared to other treatments. This positive development could strengthen INGREZZA's market position, though the company still faces challenges related to payer access and reimbursement.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | TD Cowen | $200 | $175 | +14% |
| 2025-11-11 | Morgan Stanley | $173 | $178 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | TD Cowen | main | Buy |
| 2025-11-11 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 17.0x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.5B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 17.0 |
| Current P/E | 22.5 |
| YoY Growth | 32.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.3% to 3.4% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.6pp (needs >4.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. AM_20 at 5.8% shows strong absolute momentum above own 20MA. Outperforming sector by 5.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.10), confirming momentum. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.42% (CS: 77) | Neutral |
| RSI_14 | 65.5 | Neutral |
| MACD Histogram | 1.10 | Bullish |
| vs SMA20 | 1.058x | Above |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.215x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $155.51
- **Stop Loss:** $146.61 (5.7% risk)
- **Target:** $173.31 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $8,708.56
- **Portfolio %:** 8.71%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*